Chou, Yu-Chi 周祐吉

 

YCChou6x7研究助技師


E-mail: Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它
Telephone: (Office) 02-2787-1239 | (Lab) 02-2789-8763 ext 16

 

EDUCATION AND POSITIONS HELD:

  • B.Sc., Department of Plant Pathology and Microbiology, National Taiwan University, Taiwan, 1992-1996
  • M.Sc., Microbiology and Immunology, National Yang-Ming University, Taiwan, 1996-1998
  • Ph.D., Microbiology and Immunology, National Yang-Ming University, Taiwan, 1998-2004
  • Postdoctoral Fellow, Institute of Molecular Biology, Academia Sinica, Taiwan, 2005-2016
  • Assistant Manager, National RNAi Core Facility Platform, Academia Sinica, Taiwan, 2013-2015
  • Manager, Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and CRISPR (C6 core facility), Academia Sinica, Taiwan, 2015-present
  • Assistant Research Specialist, Genomics Research Center, Academia Sinica, Taiwan, 2016-present

HONORS:

  • Outstanding Academic Paper Award, Liver Disease Prevention and Treatment Research Foundation, Taiwan, 2005
  • Special Award for Academic Research of Hepatitis B Virus, Liver Disease Prevention and Treatment Research Foundation, Taiwan, 2008

PATENTS:

  • RREB1 as A Target for Therapy of Thalassemias and Sickle Cell Anemia. US 13/008,279; TW I432730; Inventors: Chou YC, Chen RL and Shen CK
  • Novel Compounds for Therapy of β-Thalassemia and Sickle Cell Disease. US 8,822,491; EP 12747213.2; CN 201280009511.9; TW I466,670 (Technology transfer to PharmaEssentia Crop.; NT 20,000,000); Inventors: Chou YC and Shen CK
  • N-substituted 1,8-naphthalimide derivatives are potential compounds for treating β-thalassemia and sickle cell disease. US 14/787,885; TW I536,993; CN 2013800638764 (Technology transfer in preparation); Inventors: Chou YC, Su TL and Shen CK

FACILITY MANAGEMENT / EXPERTISE:

We devote to provide various gene manipulating reagents, including RNAi, miRNA, miRNA sponges and CRISPR/Cas resources, for researchers. This core facility can perform genome-scale or small-scale pooled screenings by using RNAi, miRNA or CRISPR/Cas resource. We can assist the establishment of cell lines with gene knockout or knock-in by CRISPR/Cas techniques. Moreover, we also perform MOA studies for high-throughput screenings carried out by small-molecule platforms and antibody phage display platforms.

主要支援各研究團隊進行各種標靶式基因調控實驗的需求,包括提供干擾型核醣核酸、微核醣核酸、微核醣核酸海綿以及CRISPR/Cas等試劑資源。本核心設施提供全基因方位或是小規模的基因篩選實驗(干擾型核醣核酸、微核醣核酸以及CRISPR/Cas)。利用CRISPR/Cas技術,我們可以協助研究學者建立基因剔除或基因置入之細胞株。此外,本核心設施同時協助超高速小分子藥物篩選以及抗體藥物(噬菌體表達)篩選平台,進行藥物標的基因之鑑定分析。

SELECTED PUBLICATIONS:

  • Chen YF, Chong CL, Wu YC, Wang YL, Tsai KN, Kuo TM, Hong MH, Hu CP, Chen ML, Chou YC*, Chang C*, 2015, “Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPalpha Expression.”, PloS one, 10(6), e0131743. (SCI)
  • Chou YC, Chen RL, Lai ZS, Song JS, Chao YS, Shen CK*, 2015, “Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.”, Molecular and cellular biology, 35(14), 2541-53. (SCI)
  • Wang YL, Liou GG, Lin CH, Chen ML, Kuo TM, Tsai KN, Huang CC, Chen YL, Huang LR, Chou YC*, Chang C*, 2015, “The inhibitory effect of the hepatitis B virus singly-spliced RNA-encoded p21.5 protein on HBV nucleocapsid formation.”, PloS one, 10(3), e0119625. (SCI)
  • Chou YC, Lai MM, Wu YC, Hsu NC, Jeng KS, Su WC*, 2015, “Variations in genome-wide RNAi screens: lessons from influenza research.”, Journal of clinical bioinformatics, 5, 2.
  • Chen YJ, Wu SY, Chen CC, Tsao YL, Hsu NC, Chou YC*, Huang HL*, 2014, “Armillaria mellea component armillarikin induces apoptosis in human leukemia cells”, Journal of Functional Foods, 6, 196-204. (SCI)
  • Huang CC, Kuo TM, Yeh CT, Hu CP, Chen YL, Tsai YL, Chen ML, Chou YC*, Chang C*, 2013, “One single nucleotide difference alters the differential expression of spliced RNAs between HBV genotypes A and D.”, Virus research, 174(1-2), 18-26. (SCI)
  • Hong MH, Chou YC, Wu YC, Tsai KN, Hu CP, Jeng KS, Chen ML, Chang C*, 2012, “Transforming growth factor-beta1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4alpha expression.”, PloS one, 7(1), e30360. (SCI)
  • Chong CL, Chen ML, Wu YC, Tsai KN, Huang CC, Hu CP, Jeng KS, Chou YC*, Chang C*, 2011, “Dynamics of HBV cccDNA expression and transcription in different cell growth phase.”, Journal of biomedical science, 18, 96. (SCI)
  • Chen RL, Chou YC, Lan YJ, Huang TS, Shen CK*, 2010, “Developmental silencing of human zeta-globin gene expression is mediated by the transcriptional repressor RREB1.”, The Journal of biological chemistry, 285(14), 10189-97. (SCI)
  • Chou YC, Chen ML, Hu CP, Chen YL, Chong CL, Tsai YL, Liu TL, Jeng KS, Chang C*, 2007, “Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA.”, HEPATOLOGY, 46(3), 672-81. (SCI)
  • Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL, Liu YC, Hu CP, Chang C*, 2005, “Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method.”, Journal of virology, 79(3), 1813-23. (SCI)